DHAPP's goal is to maximize program impact by focusing on the drivers of the epidemic specific to the military, and to support the development of interventions and programs to improve HIV prevention, care, and treatment.
This BAA is intended to solicit existing partners and establish new partners in order to expand the DHAPP program.Interested sources should submit proposals identifying their plans and capabilities per information in Section IV, Application and Submission information.
Proposals should focus on rapidly extending HIV/AIDS services.Respondents are encouraged to target specific needs with a practical business plan, using small grass-roots organizations to provide community-based services as a way to enhance organic capabilities and sustainability.
Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD)
Agency:National Institutes of Health
Number:PAR-10-161
Deadline:Letters of Intent: October 8, 2010; October 7, 2011; October 9, 2012 Full Applications: November 8, 2010; November 8, 2011; November 8, 2012
The goal of this Funding Opportunity Announcement issued by the National Institute of Allergy and Infectious Diseases (NIAID) is to facilitate the translation of innovative and promising basic science-derived vaccine concepts for prophylactic HIV vaccines to initial clinical trials by providing the critical resources necessary for achieving this goal. The Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) is a mechanism that enables investigators to conduct clinical research studies aimed at addressing specific scientific questions and vaccine concepts most appropriately tested in humans. To fulfill this goal, an IPCAVD award is intended to provide assistance to meritorious competitive projects in 3 areas: (1) support for basic hypothesis-driven science to advance development of the vaccine concept by facilitating non-human primate (NHP) proof-of-concept studies and down-selection to the best lead candidate; (2) access to resources for determining whether the vaccine concept is clinically feasible by determining whether a candidate vaccine successfully addresses FDA requirements for performing clinical testing, by determining the feasibility of manufacturing cGMP lots of the vaccine and by determining vaccine safety by conducting the required toxicology and pharmacology safety studies; and (3) support for the initial human clinical study central to addressing the proposed scientific question. A preclinical research project application alone is not appropriate for this announcement.
Consortia for AIDS Vaccine Research in Nonhuman Primates
Agency:National Institutes of Health
Number:RFA-AI-10-004
Deadline:Letters of Intent Receipt Date: October 1, 2010 Application Due Date: November 3, 2010
This Funding Opportunity Announcement issued by the National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Health (NIH), solicits applications that propose to establish a collaborative, multidisciplinary research program to investigate viral and host events that occur at the earliest stages of mucosal infection of nonhuman primates (NHP) with simian immunodeficiency virus (SIV), and to identify vaccines and vaccine-induced immune responses that can block initial infection, prevent establishment of systemic infection, or significantly reduce pathogenic effects of SIV infection.
The NIH Institutes listed above invite research grant applications to conduct studies designed to develop innovative approaches that would contribute to our understanding of the mechanisms that impact on the virulence of infections involving two or more microorganisms or strains of microorganisms (with the exception of HIV). The total project period for an application submitted in response to this funding opportunity may not exceed two years.
